A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis.

The effect of interferon-beta in multiple sclerosis is modest and many patients do not respond to treatment. To date, no single biomarker reliably correlates with responsiveness to interferon-beta in multiple sclerosis. In the present study, genome-wide expression profiling was performed in peripheral blood mononuclear cells from 47 multiple sclerosis patients treated with interferon-beta for a minimum of 2 years and classified as responders and non-responders based on clinical criteria. A validation cohort of 30 multiple sclerosis patients was included in the study to replicate gene-expression findings. Before treatment, interferon-beta responders and non-responders were characterized by differential expression of type I interferon-induced genes with overexpression of the type interferon-induced genes in non-responders. Upon treatment the expression of these genes remained unaltered in non-responders, but was strongly upregulated in responders. Functional experiments showed a selective increase in phosphorylated STAT1 levels and interferon receptor 1 expression in monocytes of non-responders at baseline. When dissecting this type I interferon signature further, interferon-beta non-responders were characterized by increased monocyte type I interferon secretion upon innate immune stimuli via toll-like receptor 4, by increased endogenous production of type I interferon, and by an elevated activation status of myeloid dendritic cells. These findings indicate that perturbations of the type I interferon signalling pathway in monocytes are related to lack of response to interferon-beta, and type I interferon-regulated genes may be used as response markers in interferon-beta treatment.

[1]  M. Krumbholz,et al.  Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. , 2008, Brain : a journal of neurology.

[2]  B. Becher,et al.  Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. , 2008, Immunity.

[3]  Pablo Villoslada,et al.  Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. , 2008, Archives of neurology.

[4]  À. Rovira,et al.  Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients , 2008, Multiple sclerosis.

[5]  G. Lemke,et al.  TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response , 2007, Cell.

[6]  R. Steinman,et al.  Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program , 2007, The Journal of Experimental Medicine.

[7]  A. Minagar,et al.  Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis: A preliminary study , 2007, Journal of Neuroinflammation.

[8]  R. Steinman,et al.  Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program , 2007, The Journal of experimental medicine.

[9]  E. Coccia,et al.  Sensitization to TLR7 Agonist in IFN-β-Preactivated Dendritic Cells1 , 2007, The Journal of Immunology.

[10]  S. Miller,et al.  CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ TH-17 cells in relapsing EAE , 2007, Nature Immunology.

[11]  C. Wijbrandts,et al.  Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients , 2007, Annals of the rheumatic diseases.

[12]  P. Gregersen,et al.  An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients is Associated with Disease Activity , 2007, Molecular medicine.

[13]  E. Coccia,et al.  Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells. , 2007, Journal of immunology.

[14]  A. Lutterotti,et al.  Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients , 2006, Multiple sclerosis.

[15]  G. Freeman,et al.  Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response1 , 2006, The Journal of Immunology.

[16]  C L Verweij,et al.  A subtype of multiple sclerosis defined by an activated immune defense program , 2006, Genes and Immunity.

[17]  E. Coccia,et al.  Differential responsiveness to IFN‐α and IFN‐β of human mature DC through modulation of IFNAR expression , 2006 .

[18]  Xiaodong Zhou,et al.  Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. , 2006, Rheumatology.

[19]  C. Lucchesi,et al.  Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  X. Montalban,et al.  Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.

[21]  E. Coccia,et al.  Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression. , 2006, Journal of leukocyte biology.

[22]  M. Panelius,et al.  Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS , 2005, Journal of Neuroimmunology.

[23]  P. Park,et al.  Discovering statistically significant pathways in expression profiling studies. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Speed,et al.  Colon cancer prognosis prediction by gene expression profiling , 2005, Oncogene.

[25]  L. Semendric,et al.  Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector , 2005, Hepatology.

[26]  B. Becher,et al.  Experimental autoimmune encephalomyelitis repressed by microglial paralysis , 2005, Nature Medicine.

[27]  L. Greller,et al.  Transcription-Based Prediction of Response to IFNβ Using Supervised Computational Methods , 2004, PLoS biology.

[28]  M. Peterson,et al.  Coordinate overexpression of interferon‐α–induced genes in systemic lupus erythematosus , 2004 .

[29]  F. Watzinger,et al.  Real-Time Quantitative PCR Assays for Detection andMonitoring of Pathogenic Human Viruses in ImmunosuppressedPediatricPatients , 2004, Journal of Clinical Microbiology.

[30]  S. Hanash,et al.  Global and Distinct Targets of IRF-5 and IRF-7 during Innate Response to Viral Infection* , 2004, Journal of Biological Chemistry.

[31]  G. Lesinski,et al.  Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. , 2004, Journal of the National Cancer Institute.

[32]  E. Coccia,et al.  Viral infection and Toll‐like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte‐derived dendritic cells , 2004, European journal of immunology.

[33]  M. Peterson,et al.  Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[34]  P. Fisher,et al.  Expression regulation and genomic organization of human polynucleotide phosphorylase, hPNPase(old-35), a Type I interferon inducible early response gene. , 2003, Gene.

[35]  T. Stewart.  Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. , 2003, Cytokine & growth factor reviews.

[36]  C. Bao,et al.  Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray , 2003, Genes and Immunity.

[37]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[38]  Carlos Nos,et al.  Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials , 2002, Annals of neurology.

[39]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[40]  N. Kadowaki,et al.  Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.

[41]  F. Belardelli,et al.  Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. , 2001, Immunity.

[42]  Weir,et al.  Low Levels of Interferon‐α Induce CD86 (B7.2) Expression and Accelerates Dendritic Cell Maturation from Human Peripheral Blood Mononuclear Cells , 1999, Scandinavian journal of immunology.

[43]  B. Williams,et al.  Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays , 1998 .

[44]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[45]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[46]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[47]  C. Heusser,et al.  Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells , 1993, The Journal of experimental medicine.

[48]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[49]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .